The First Year-end report from NeoDynamics
Year-end report 2018
Fourth quarter 2018
Significant events during the period
Significant events after the period
Finally on our way
Every hour, one woman in Sweden is diagnosed with breast cancer.
An early and accurate diagnosis can save lives and improve quality of life.
In recent years, significant technical advances in many areas have improved patient outcomes. Enhanced imaging and ultrasound machines have made it possible to identify small tumors. More effective medicines and tailored radiation treatments have led to improved treatment results. But a very important part of the process is to obtain tissue samples of sufficient quality and volume from patients with suspicious lesions. The biopsy technique and equipment used in health care today have obvious deficiencies, especially in tissue sampling in difficult cases such as lymph nodes in the axilla, small tumors, dense breast tissue, and tumors located near the chest.
Based on research carried out at KTH Royal Institute of Technology and Karolinska Institutet, NeoDynamics has developed the NeoNavia biopsy system, a patented new technology for precision placement of biopsy needles with the help of micro-pulses. The system has been developed with leading clinical experts in Sweden, Germany and the UK to handle today’s challenges such as sampling of very small lesions in difficult-to-reach locations, as well as to support “precision medicine”. NeoNavia includes a number of unique functionalities that can improve the diagnosis of breast cancer.
Important milestones reached in 2018
Heavy investments were made in 2018 in our new technology, and we had more than 30 technicians working on different tasks to finalize our biopsy system. NeoDynamics has developed the base unit, the driver and the three different probes (needles) which are all ready for use with micro-pulses. Our business model is very cost effective. We have a small and competent organization, we have an agile way of working, and we connect with relevant expertise if and when it is needed.
We are now entering the final development phase, focusing on verification and validation as well as regulatory submissions. From an economic perspective, this is now a less hectic period with considerably lower product development costs compared with 2018.
It is with great satisfaction that I am able to conclude that we have followed our development plan and delivered on our targets. In parallel with our development, we have initiated a larger clinical program in Germany with eight university clinics which are using our CE-approved study version of NeoNavia to document clinical experience. The NeoNavia study aims to show improvements in biopsies taken from axilla lymph nodes. We paid all the product costs for the German study in 2018 as well as those associated with other studies planned for 2019. This means there will be no product costs for our studies in 2019.
During the first half of 2018 we arranged for a convertible loan of SEK 11.4 M which was converted into shares during the second half of 2018. In parallel with this, we arranged a
bridging loan during the summer which was offset against shares in the IPO. All loans were repaid in connection with the transfer of the IPO money (SEK 50.5 M). After clearance of loans and payment of costs related to the share issue and the listing, the company had SEK 25,4 M in cash at year-end. It is estimated that this money will be sufficient for the running of operations until the end of 2019.
NeoDynamics is a public company and our shares were listed on Spotlight Stock Market on December 7. The new issue of shares was directed to and offered to the stock market during October and November.
Key activities: 2019
The formal verification and validation phase of NeoNavia begins during the first quarter of 2019, and we will complete all technical documentation according to the regulatory requirements to obtain regulatory approvals. Application for CE approval will be submitted during the second half of 2019, and an FDA application (510K) will also be submitted for approval in the US by the end of 2019.
During 2019, an English clinical study will be launched in collaboration with a number of major cancer clinics in the UK. At the same time, we are increasing our commitment and our marketing activities in the UK. The review and analysis of suitable sales channels and alternative partners are other important activities that will be undertaken in the coming year.
NeoNavia is an important Swedish innovation. In 2019, we will deepen our cooperation with the major university clinics in Sweden to increase knowledge of NeoNavia and generate interest in participation in user tests during the autumn.
I look forward to a very rich year with many important milestones in the Company’s development, and also look forward to offering women who suffer from breast cancer a better and more reliable diagnosis in the near future.
Anna Eriksrud, CEO, NeoDynamics
During the period January – December 2018, the Company has developed according to plan, with the main costs being related to product development, clinical studies and personnel. NeoDynamics applies a policy of capitalization of development costs to intangible assets, but not of personnel costs.
During the year, the Company has not had any product sales since all products have been used in clinical trials. Capitalized expenses accounted for 24 877 TSEK (11 021) of the reported revenues of 24 978 TSEK (11 298).
Operating income before depreciation for the year amounted to -15 058 TSEK (-7 054). Depreciation and write-downs for the year amounted to -560 TSEK (-419). Non-recurring items for the year amounted to -156 TSEK (-10) while financial expenses amounted to -2 581 TSEK (-4). Profit before tax for the year and after tax amounted to -18 200 TSEK (-7477).
On December 31, 2018, the equity ratio was 90 (74) percent. Shareholders’ equity amounted to
74 563 TSEK, compared with 26 706 TSEK at the same time last year. As of December 31, 2018, the Company’s cash and cash equivalents amounted to 25 654 TSEK (5 525). Total assets for the Company at the same time amounted to 82 455 TSEK compared with 36 077 TSEK the previous year.
The Board’s assessment is that the working capital requirement in 2019 will be met by using available cash and net proceeds from a planned new issue through an option program that may raise approximately 24 MSEK in new equity at the end of the year. Alternatively the business plan may be revised and adjusted.
The company is in a build-up phase during which the business is not affected by seasonal effects. In 2018, significant funds were invested in the development of the NeoNavia biopsy system.
NeoDynamics shares have been listed on the Spotlight Stock Market since December 7, 2018. The short name is “NEOD” and the ISIN-code is SE0011563410. The Company has only one class of shares. Each share carries equal rights to share in the Company’s assets and earnings.
As of December 31, 2018, the total number of shares in issue was 15 303 520 (6 908 000). During 2018 there have been two splits (10:1 och 100:1) and the previous year’s number of shares
(6 908) has been multiplied by 1,000 for increased comparability.
The table below shows NeoDynamics’ 10 largest owners of votes and shares at year-end.
|1||Boai NKY Medical Holdings Ltd, China||4,922,544||32.17%|
|2||M2 Capital Management AB||1,278,457||8.35%|
|3||Gryningskust Holding AB||914,900||5.98%|
|5||ADB Invest AB||360,700||2.36%|
|7||Rentability Sweden AB||290,694||1.90%|
|9||Humlan Fastighetsutveckling AB||240,000||1.57%|
|10||Espander Life Science Partner AB||200,000||1.31%|
Annual General Meeting
NeoDynamics’ Annual General Meeting will be held on May 23, 2019, in Lidingö, Sweden. The annual report will be available for download on the Company’s website (www.neodynamics.se)
by April 20, 2019 at the latest.
The Board of Directors proposes no dividend for the fiscal year 2018.
Annual report Apr 20, 2019
Interim report (Jan-Mar) May 21, 2019
Annual General Meeting May 23, 2019
Interim report (Jan-Jun) Aug 21, 2019
Interim report (Jan-Sep) Nov 21, 2019
Risks and uncertainties
A number of risk factors may have a negative impact on NeoDynamics AB’s operations. It is therefore essential to consider the relevant risks besides the Company’s growth opportunities. For a detailed description of the risks attributable to the Company and its shares, reference is made to the prospectus published by the Board in October 2018.
The year-end report has been prepared in accordance with the Annual Accounts Act and with the application of the Swedish Accounting Standards Board’s general advice: BFNAR 2012: 1 Annual Report and Consolidated Financial Statements (K3). The activation model in the general council has been applied for intangible assets. The company’s assets and liabilities are stated at cost and nominal value unless otherwise stated.
This report has not been reviewed by the company’s auditor.
The Board of Directors and the CEO hereby certify that the year-end report provides a true and fair view of NeoDynamics’ operations.Year-end report submitted
Lidingö, February 21, 2019
Anna Eriksrud Ingrid Salén Carina Bolin
CEO Chairman of the Board Board member
Claes Pettersson Jörgen Vrenning Xiaojun Xu
Board member Board member Board member
NeoDynamics AB, 559014–9117
For further information, please contact:
Anna Eriksrud, tel +46 708 444 966 or email@example.com
Jörgen Vrenning, tel +46 708 519 648 or firstname.lastname@example.org
NeoDynamics has made this information public in accordance with the EU Market Abuse Regulation. The information was submitted for publication at 08.45a.m. CET on February 21, 2019.
NeoDynamics in brief
NeoDynamics AB (publ) is a Swedish medical technology company that focuses on improving the diagnosis and treatment of breast cancer. The company has an innovative biopsy system, NeoNavia®, which is in a late stage of development. The biopsy system is based on a patented micro-pulse technology which is based on early research carried out at KTH Royal Institute of Technology and Karolinska Institutet. The system is designed to offer physicians and patients precise and accurate tissue sampling with a large exchange of tissue and thus the best possible conditions for an accurate diagnosis. NeoNavia® is being evaluated at leading clinics in the UK, Germany and Sweden. The commercial launch of the system is expected to take place during the first quarter of 2020.